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Abstract
Human Tetherin/BST-2 has recently been identified as a cellular antiviral factor that blocks the release of various enveloped
viruses. In this study, we cloned a cDNA fragment encoding a feline homolog of Tetherin/BST-2 and characterized the
protein product. The degree of amino acid sequence identity between human Tetherin/BST-2 and the feline homolog was
44.4%. Similar to human Tetherin/BST-2, the expression of feline Tetherin/BST-2 mRNA was inducible by type I interferon
(IFN). Exogenous expression of feline Tetherin/BST-2 efficiently inhibited the release of feline endogenous retrovirus RD-114.
The extracellular domain of feline Tetherin/BST-2 has two putative N-linked glycosylation sites, N79 and N119. Complete loss
of N-linked glycosylation by introduction of mutations into both sites resulted in almost complete abolition of its antiviral
activity. In addition, feline Tetherin/BST-2 was insensitive to antagonism by HIV-1 Vpu, although the antiviral activity of
human Tetherin/BST-2 was antagonized by HIV-1 Vpu. Our data suggest that feline Tetherin/BST-2 functions as a part of IFN-
induced innate immunity against virus infection and that the induction of feline Tetherin/BST-2 in vivo may be effective as a
novel antiviral strategy for viral infection.
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Introduction
Human Tetherin/BST-2 (also referred to as CD317 or
HM1.24) was first identified as a cellular restriction factor that
blocks the release of HIV-1 in the absence of the viral accessory
protein, Vpu [1]. Subsequent studies have shown that human
Tetherin/BST-2 also inhibits the release of other retroviruses,
filoviruses, arenaviruses, and herpesviruses [1–7].
Tetherin/BST-2 is a type II integral membrane protein
consisting of an N-terminal cytoplasmic tail, a transmembrane
domain, followed by an extracellular domain important for
dimerization, and a glycophosphatidyl inositol (GPI) lipid anchor
at its C-terminus [8]. The extracellular domain of Tetherin/BST-2
has two putative N-linked glycosylation sites, which are highly
conserved at the same positions among human, rhesus monkey,
dog, pig, rat, andmouse,andorthologshave been identifiedthat are
actually glycosylated heterogeneously [8,9]. Previously, we showed
that N-linked glycosylation is dispensable for the antiviral activity of
human Tetherin/BST-2against Lassa and Marburg viruses[6]. On
the other hand, there are conflicting data regarding the role of N-
linked glycosylation on the antiviral activity of human Tetherin/
BST-2 against HIV-1. Andrew et al. reported that N-linked
glycosylation is not important for inhibition of HIV-1 virus release,
while Perez-Caballero et al. showed that N-linked glycosylation,
especially at the second site, is important for the antiviral activity of
human Tetherin/BST-2 against HIV-1 [10,11].
Human Tetherin/BST-2 is constitutively expressed in termi-
nally differentiated B cells, bone marrow stromal cells, and
plasmacytoid dendritic cells, and is upregulated in various cell
types on treatment with type I and type II interferon (IFN) [12,13].
Therefore, Tetherin/BST-2 is thought to be involved in antiviral
host defense as an innate immunity mechanism. It has also been
reported that several viruses encode antagonists, such as HIV-1
Vpu, HIV-2 Env, SIVmac/cpz/gor Nef, Ebola virus GP, and
Kaposi’s sarcoma-associated herpesvirus (KSHV) K5, which
antagonize the antiviral activity of Tetherin/BST-2 [1,5,7,14–17].
The cat genome contains an infectious endogenous retrovirus
(ERV) named RD-114 [18]. Several feline cell lines including
Crandell-Rees feline kidney (CRFK) cells constitutively express
infectious RD-114 [19,20]. Therefore, there is concern regarding
contamination by RD-114 in vaccines, as these cells have been
used to grow several live attenuated vaccines for pets and cattle. In
fact, we recently reported the isolation of an infectious RD-114 in
a proportion of live attenuated vaccines for pets [21]. RD-114 is
considered to be a polytropic virus, since it efficiently infects feline
cells as well as human and dog cells [19,22]. Although the
pathogenicity of RD-114 has not been determined, it has potential
risks in that interspecies transmission may induce unpredictable
diseases. However, it is very difficult to completely exclude the
proviral DNA of RD-114 from cells, as ERVs are usually
integrated into multiple loci in the host chromosomes [18].
In this study, to investigate the potential of Tetherin/BST-2 to
regulate the production of RD-114 from cells, we cloned and
characterized the feline homolog of Tetherin/BST-2 and
examined its ability to restrict the release of RD-114 from cells.
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Cells
Human embryonic kidney (HEK) 293T cells, Crandell-Rees
feline kidney (CRFK) cells, and QN10S cells were maintained at
37uC in a 5% CO2 incubator in Dulbecco’s modified Eagle’s
medium (Sigma, St. Louis, MO) supplemented with 10% fetal
bovine serum and penicillin/streptomycin. FL74 cells (feline T-
lymphoblastoid cell line) were maintained at 37uC in a 5% CO2
incubator in RPMI 1640 medium (Sigma) supplemented with 10%
fetal bovine serum and penicillin/streptomycin.
Cloning of the feline Tetherin/BST-2 gene
The primer TethConF (59-TCACCATCAAGGCCAACAGC-
39), corresponding to a sequence conserved among Tetherin/
BST-2 genes from various species reported to date, was designed
to clone feline Tetherin/BST-2. RT-PCR was performed using a
PrimeSTAR RT-PCR Kit (Takara, Shiga, Japan), with total
RNA extracted from IFN-treated CRFK cells as the template,
according to the manufacturer’s protocols. Partial cDNA
fragments of feline Tetherin/BST-2 with high degrees of identity
to human Tetherin/BST-2 were amplified. To determine the
initiation site of the coding sequence (CDS) of feline Tetherin/
BST-2, 59-RACE was performed with a Takara 59-Full RACE
Core Set according to the manufacturer’s protocols (Takara),
using total RNA extracted from IFN-treated CRFK, FL74, or
QN10S cells as the template. The feline Tetherin/BST-2 gene
was identified. The intact CDS of feline Tetherin/BST-2 was
amplified again by RT-PCR, and then cloned into pCDNFL,
which was constructed from pcDNA3.1 (Invitrogen, Carlsbad,
CA) to express a protein containing a FLAG-tag at the N-
terminus [6,23]. The expression plasmid for feline Tetherin/
BST-2 was named pfelTeth-FL.
Plasmids
The plasmids carrying human Tetherin/BST-2 or HIV-1 Vpu,
pTeth-FL or pVpu-Myc, respectively, and the plasmid containing
an intact infectious clone of RD-114, pTERD-114, were described
previously [6,24]. The glycosylation mutants of feline Tetherin/
BST-2 with asparagine to alanine substitution(s) at position 79
and/or 119, N79A, N119A, and N79A/N119A, were generated
from pfelTeth-FL using a QuikChange II site-directed mutagen-
esis kit (Stratagene, La Jolla, CA).
Quantification of feline Tetherin/BST-2 mRNA by
real-time RT-PCR
To examine the induction of feline Tetherin/BST-2 by IFN,
CRFK cells were treated for 24 h in the presence of 100 or 1,000
units/ml IFN-aA/D (Sigma) and then total cellular RNA was
extracted from pelleted cells using an RNeasy Mini kit (Qiagen,
Valencia, CA). Real-time RT-PCR was performed using the feline
Tetherin/BST-2 primers, 59-GGAGTGTCACGGTGTCACCC-
39 (forward) and 59-CCTCAATCTCTCCCCGAAGCTC-39
(reverse), and the 18S rRNA primers, 59-GACGACCCATTC-
GAACGTCT-39 (forward) and 59-TGCTGCCTTCCTTG-
GATGTG-39 (reverse). Amplification was performed with a
One-Step SYBR RT-PCR Kit (Takara) according to the
manufacturer’s protocols using a Smart Cycler II System
(Cepheid, Sunnyvale, CA).
Figure 1. Comparison of the predicted amino acid sequences of cat, dog, pig, mouse, and human Tetherin/BST-2 homologs. Cat
(CRFK, FL74, and QN10S cells), dog, pig, mouse, and human Tetherin/BST-2 sequences were analyzed and aligned using GENETYX ver. 8 (GENETYX,
Tokyo, Japan). The predicted transmembrane domain is boxed. Three Cys residues in the extracellular domain, which are important for dimerization,
are shown with a red background. Two putative glycosylation sites are shown with a blue background. Ser residues of the predicted cleavage site
prior to addition of a GPI anchor are shown with a yellow background.
doi:10.1371/journal.pone.0018247.g001
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RD-114
To examine the antiviral activity of Tetherin/BST-2, 293T cells
(2610
5) were cotransfected with pTERD-114 (100 ng) and either
pTeth-FL or pfelTeth-FL (25, 50, 100, or 200 ng) using Trans-IT
LT-1 (Mirus Bio Corp., Madison, WI). Forty-eight hours after
transfection, virion-containing culture supernatants were clarified
by centrifugation (10,0006g; 15 min) and virions were pelleted
through a 16.5% sucrose cushion by ultracentrifugation
(348,0006g; 40 min at 4uC). Cells were lysed with lysis buffer A
[25]. Virion- and cell-associated proteins were analyzed by
Western blotting using anti-RD-114 Gag antibody, anti-FLAG
M2 antibody (Sigma), and anti-actin antibody (Sigma) as described
previously [6,24]. The intensities of the bands for virion- and cell-
associated Gag were quantified using a Fuji LAS3000 imaging
system (Fuji Film, Tokyo, Japan). The control vector (virus p28
CA/
virus p28
CA + cellular p28
CA + p68
Gag) was set to 100%. Virus
production was also examined by real-time RT-PCR. Viral RNAs
were extracted from pelleted virions using a QIAamp Viral RNA
Mini Kit (Qiagen). After DNaseI treatment, real-time RT-PCR
was performed using the previously described primers targeting
the RD-114 pol region [26]. Amplification was performed as
described above.
Results
Cloning and sequence analysis of feline Tetherin/BST-2
Molecular cloning of complete coding region of feline Tetherin/
BST-2 was carried out by RT-PCR and 59-RACE using RNA
extracted from three kinds of feline cell lines, CRFK, FL74, and
QN10S cells, treated with IFN. The amino acid sequences of
Tetherin/BST-2 from CRFK and FL74 cells were completely
identical, while that from QN10S cells was different from those
from CRFK and FL74 cells at three positions, 59, 80, and 116
(Figure 1). The nucleotide sequence of the coding region of feline
Tetherin/BST-2 and the corresponding protein sequence have
been deposited in DDBJ (AB564550). Furthermore, Figure 1
shows the amino acid sequence alignment of Tetherin/BST-2
from cat, dog (GenBank XM_860510), pig (GenBank
NM_001161755), mouse (GenBank NM_198095), and human
(GenBank NM_004335). The degree of sequence identity between
feline Tetherin/BST-2 and those of dog, pig, mouse, and human
were 57.7%, 48.7%, 42.5%, and 44.4%, respectively. Three
cysteine residues in the extracellular domain, which appear to be
important for dimer formation, are conserved among all species.
Two putative N-linked glycosylation sites are conserved at the
same positions among all species other than cat. The glycosylation
site in the central region of extracellular domain, N79, is conserved
in feline Tetherin/BST-2, while another glycosylation site, N119,
is present in the relatively C-terminal region of the extracellular
domain of feline Tetherin/BST-2, but not in the region close to
the transmembrane domain as in other species. We also found that
the N-terminal cytoplasmic tail of feline Tetherin/BST-2 is shorter
than those of other species.
Induction of feline Tetherin/BST-2 in feline cells by IFN
It has been reported that human Tetherin/BST-2 is inducible
by type I IFN [1,12]. To investigate whether the expression of
feline Tetherin/BST-2 is induced by type I IFN, we treated
CRFK cells with 100 or 1,000 units/ml of IFN-a A/D for 24 h
and determined the level of feline Tetherin/BST-2 mRNA by
quantitative real-time RT-PCR. Treatment with 100 or 1,000
units/ml of IFN-a induced increases of 75- and 320-fold in feline
Tetherin/BST-2 mRNA level, respectively, compared to untreat-
ed cells (Figure 2A). CRFK cells constitutively express infectious
endogenous retrovirus, RD-114. IFN treatment reduced RD-114
release from CRFK cells with a concomitant increase in feline
Tetherin/BST-2 expression (Figure 2B), suggesting that feline
Tetherin/BST-2 inhibits release of RD-114 virus particles from
cells.
Antiviral activity of feline Tetherin/BST-2 against RD-114
To directly examine whether feline Tetherin/BST-2 has
inhibitory activity against RD-114 virus release, the expression
plasmid for feline Tetherin/BST-2 originated from CRFK cells or
human Tetherin/BST-2 was cotransfected with the RD-114
infectious clone into 293T cells and RD-114 production was
analyzed by Western blotting and real-time RT-PCR assay. As
shown in Figure 3A, dose-dependent reductions in RD-114 release
were observed with increasing expression levels of human and
feline Tetherin/BST-2. Quantitative analyses of the amounts of
RD-114 virions released from cells were also carried out by
Western blotting and real-time RT-PCR assay (Figure 3B and C).
The inhibition of RD-114 virus release by feline Tetherin/BST-2
was demonstrated by both Western blotting and real-time RT-
PCR assay. Antiviral activity of feline Tetherin/BST-2 against
Figure 2. Induction of Tetherin/BST-2 and reduction of RD-114
particle release by IFN treatment of feline cells. CRFK cells were
treated with 100 or 1,000 U/ml of IFN-a for 24 h. (A) feline Tetherin/BST-
2 mRNA and 18S rRNA were quantified by real-time RT-PCR. The
numbers of feline Tetherin/BST-2 mRNA copies were normalized to one
copy of 18S rRNA. Histograms represent the averages from three
independent experiments (6 standard deviation of the mean). (B) RD-
114 viral RNA in the supernatant from IFN-treated or untreated CRFK
cells were quantified by real-time RT-PCR.
doi:10.1371/journal.pone.0018247.g002
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BST-2, although feline and human Tetherin/BST-2 were
expressed at similar levels in cells transfected with the same
amounts of each expression plasmid. We also confirmed that feline
Tetherin/BST-2 originated from QN10S cells inhibits RD-114
production at the similar level to feline Tetherin/BST-2 originated
from CRFK cells (data not shown).
Importance of N-linked glycosylation for antiviral activity
To examine the role of N-linked glycosylation of feline
Tetherin/BST-2 in its antiviral function, we analyzed the effects
of exogenous expression of mutants with a single or multiple
mutations in the N-linked glycosylation sites (N79A, N119A, and
N79A/N119A) on RD-114 production. 293T cells were cotrans-
fected with the RD-114 infectious clone and increasing amounts of
the expression plasmid for wild-type or mutant feline Tetherin/
BST-2. Wild-type feline Tetherin/BST-2 was detected as triplet
bands, while N79A and N119A mutants and N79A/N119A
mutant showed double and single band(s), respectively (Figure 4),
indicating that the upper, middle, and lower bands of triplet forms
corresponded to multiple-, single-, and non-glycosylated forms,
respectively. Exogenous expression of the N119A mutant
significantly reduced RD-114 virus release as well as wild-type,
while the inhibitory activity of the N79A mutant on the RD-114
virus release was lower than those of wild-type and N119A mutant
despite the much higher expression level (Figure 4). Furthermore,
the N79A/N119A mutant without glycosylation almost completely
lost its antiviral activity. In addition, the antiviral activity of the
N79A/N119A mutant could not be overcome by increased
expression. These results indicated that glycosylation at N119 is
not essential for the antiviral activity of feline Tetherin/BST-2,
while the loss of glycosylation at N79 or at both N79 and N119
markedly affected its antiviral activity.
Feline Tetherin/BST-2 is insensitive to antagonism by
HIV-1 Vpu
HIV-1 Vpu has been shown to antagonize the antiviral activity
of human Tetherin/BST-2, but not monkey Tetherin/BST-2. To
examine the sensitivity of feline Tetherin/BST-2 to Vpu, pVpu-
Myc, which expresses Vpu containing a Myc-tag at the N-
terminus, was cotransfected into 293T cells along with the RD-114
infectious clone and the expression plasmid for human or feline
Tetherin/BST-2. RD-114 production was analyzed by Western
blotting. As expected, Vpu expression partially rescued the RD-
114 release reduction by human Tetherin/BST-2, but not that by
feline Tetherin/BST-2 (Figure 5), indicating that Vpu has no effect
on the antiviral activity of feline Tetherin/BST-2.
Discussion
In this study, we identified feline Tetherin/BST-2 and
demonstrated the antiviral activity of feline Tetherin/BST-2.
The degree of sequence identity between feline Tetherin/BST-2
and those of dog, pig, mouse, and human were 57.7%, 48.7%,
42.5%, and 44.4%, respectively. As compared to the other cellular
antiviral factors including APOBEC3 and TRIM5 proteins, the
sequence homologies of Tetherin/BST-2 among mammalian species
are relatively low. It has been reported that the antiviral activity of
Tetherin/BST-2 require the structural features such as an N-terminal
transmembrane region, a C-terminal GPI anchor, and a proper
Figure 3. Inhibition of RD-114 particle release by feline Tetherin/BST-2. Both RD-114 vector (100 ng) and the expression vector for human
or feline Tetherin/BST-2 containing FLAG-tag (25, 50, 100, or 200 ng) were cotransfected into 293T cells. Cells and viruses were collected at 48 h after
transfection, and analyzed by Western blotting (A). The intensities of the bands for virus- and cell-associated Gag were quantified using a Fuji
LAS3000 imaging system (Fuji Film) (B). The control vector (virus p28
CA/virus p28
CA + cellular p28
CA + p68
Gag) was set to 100%. Histograms represent
the averages from three independent experiments (6 standard deviation of the mean). (C) RD-114 viral RNA in the supernatant from cells was
quantified by real-time RT-PCR.
doi:10.1371/journal.pone.0018247.g003
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sequences [11]. It would be the reason why the sequence homologies
of Tetherin/BST-2 among mammalian species are relatively low.
As expected, we found that feline Tetherin/BST-2 efficiently
inhibited the release of feline endogenous retrovirus RD-114 from
cells, although the inhibitory effect of feline Tetherin/BST-2
against RD-114 release was slightly weaker than that of human
Tetherin/BST-2 (Figure 3). RD-114 has been reported to be
produced as infectious viruses in some feline cell lines and to be
present as a contaminant in a proportion of live attenuated
vaccines for pets [21]. It is very difficult to completely exclude the
proviral DNA of RD-114 from cells, as endogenous retroviruses
are usually integrated into multiple loci of the host chromosomes.
The induction or exogenous expression of feline Tetherin/BST-2
in these feline cells may be useful as a novel strategy to reduce the
risk of the RD-114 contamination into vaccines or biological
products.
The sequence analysis of feline Tetherin/BST-2 showed that
the N-terminus of feline Tetherin/BST-2 was shorter than those of
other species (Figure 1). It has been reported that a dual-tyrosine
motif (Y-Y6–8) in the cytoplasmic domain of human Tetherin/
BST-2 is crucial for clathrin-mediated endocytosis through
recruiting AP-1 and AP-2 adaptor proteins [27,28]. Feline
Tetherin/BST-2 may be internalized via a different pathway from
the others, since feline Tetherin/BST-2 does not have this dual-
tyrosine motif in its cytoplasmic domain. These features may have
an effect on the weaker antiviral activity of feline Tetherin/BST-2
compared to human Tetherin/BST-2. However, at present, it is
not clear whether the short cytoplasmic domain and deficiency of
the dual-tyrosine motif are involved in any function of feline
Tetherin/BST-2.
Although the expression levels of N79A and N79A/N119A
mutants in cells were much higher than those of wild-type and
N119A, the loss of glycosylation at N79, but not N119, reduced
the antiviral activity of feline Tetherin/BST-2 (Figure 4). More-
over, the loss of glycosylation at both N79 and N119 almost
completely inactivated the antiviral activity against RD-114.
Glycosylation at N79 is conserved among Tetherin/BST-2
homologs from many species including cat (Figure 1), suggesting
that this glycosylation plays an important role in the structure and
function of this molecule. In addition, it has been reported
previously that N-linked glycosylation at the corresponding site of
human Tetherin/BST-2 is important for antiviral activity against
HIV-1 [11]. On the other hand, glycosylation at N119 is unique in
feline Tetherin/BST-2 and appears to be dispensable for the
antiviral activity. Although it is not clear how glycosylation of
Tetherin/BST-2 affect its antiviral activity, it has been reported
that the cell surface expression levels of the glycosylation mutants
of human Tetherin/BST-2 are less than that of WT [11]. The
lacking of glycosylation signal may affect the intracellular transport
of Tetherin/BST-2 and result in loss of the antiviral activity of
Tetherin/BST-2.
HIV-1 Vpu has been reported to recognize several amino acid
residues in the transmembrane domain of human Tetherin/BST-2
Figure 5. Feline Tetherin/BST-2 is insensitive to antagonism by
HIV-1 Vpu. Both RD-114 vector (100 ng) and the expression vector for
human or feline Tetherin/BST-2 containing FLAG-tag (200 ng), with or
without the expression vector for Vpu containing Myc-tag (1 mg), were
cotransfected into 293T cells. Cells and viruses were collected at 48 h
after transfection, and analyzed by Western blotting.
doi:10.1371/journal.pone.0018247.g005
Figure 4. Importance of N-linked glycosylation for the antiviral activity. Both RD-114 vector (100 ng) and the expression vector for wild-
type or mutant feline Tetherin/BST-2 (50, 100, or 200 ng) were cotransfected into 293T cells. Cells and viruses were collected at 48 h after
transfection, and analyzed by Western blotting (A). The intensities of the bands for virus and cell-associated Gag were quantified using a Fuji LAS3000
imaging system (B). The control vector (virus p28
CA/virus p28
CA + cellular p28
CA + p68
Gag) was set to 100%. Histograms represent the averages from
three independent experiments (6 standard deviation of the mean).
doi:10.1371/journal.pone.0018247.g004
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[29,30,31]. The activity of Vpu as a Tetherin/BST-2 antagonist
appears to be species specific, since Vpu inhibits the antiviral
activity of human Tetherin/BST-2, but not monkey Tetherin/
BST-2. In this study, we demonstrated that Vpu inhibited the
reduction of RD-114 virus release by human Tetherin/BST-2, but
not feline Tetherin/BST-2 (Figure 5). In addition, the cytoplasmic
domain of feline Tetherin/BST-2 does not have the STS motif (at
position 3-5) required for Vpu/b-TrCP-dependent ubiquitination
[32]. Thus, our data support that the activity of Vpu as a
Tetherin/BST-2 antagonist is specific for human Tetherin/BST-
2.
Similar to human Tetherin/BST-2, the feline homolog is likely
to also have antiviral activity against not only RD-114 but also a
wide variety of enveloped viruses, although we demonstrated the
antiviral activity of feline Tetherin/BST-2 against RD-114. In
addition, we showed that the expression of feline Tetherin/BST-2
was induced by type I IFN similar to human Tetherin/BST-2
(Figure 2), suggesting that Tetherin/BST-2 functions as a host
innate antiviral system against a wide variety of viruses. Analyses
of the expression pattern of feline Tetherin/BST-2 in vivo and the
mechanism of induction of Tetherin/BST-2 by IFN would be
useful for understanding the specificity (tropism) of virus
replication in tissues or cells and the development of antiviral
strategies against a wide variety of viruses.
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